手臂静脉作为下肢旁路移植自体导管的结局
单中心回顾性研究纳入42例大隐静脉不足的下肢旁路患者,均使用手臂静脉作为导管。中位无截肢生存期3.86年,30天死亡率2.4%,手术部位感染率21.4%,结论认为手臂静脉是可行的替代自体导管。
要点
- 手臂静脉可用于大隐静脉不足的下肢旁路患者
- 中位无截肢生存期为3.86年,30天死亡率为2.4%
- 手术部位感染率为21.4%,需关注术后感染
核心结论
- 手臂静脉是大隐静脉不足患者下肢动脉旁路的可行替代自体导管。
研究设计与样本
- 单中心回顾性研究,纳入2009年1月至2023年7月在同一退伍军人医疗中心接受手臂静脉下肢旁路的PAD患者,共42例旁路手术。
主要发现
- 中位无截肢生存期为3.86年(IQR 1.19-6.65年)。
- 5例患者需要大截肢(15.6%)。
- 中位主要不良肢体事件时间为0.88年(IQR 0.23-1.69年)。
- 30天死亡率为2.4%(n=1)。
- 术后并发症包括手术部位感染9例(21.4%)、血肿3例(7.1%)、早期移植物血栓形成1例(2.4%)、伤口裂开1例(2.4%)、淋巴漏1例(2.4%)。
临床怎么用
- 对于大隐静脉不足的下肢旁路患者,可考虑使用手臂静脉作为自体导管。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower extremity bypasses performed with autogernous conduit have superior patency and limb salvage. This is often performed with single segment great saphenous vein (GSV), but other options may be required for patients without available GSV. This study presents our experience utilizing arm veins as an alternative autogenous conduit for patients undergoing lower extremity bypass procedures. METHODS: A single-center retrospective study of patients at a Veterans Affairs Medical Center with peripheral arterial disease (PAD) who underwent lower extremity bypass with arm vein between January 2009 and July 2023 was performed. The primary outcomes were amputation-free survival (AFS) and major adverse limb event (MALE). Secondary outcomes include postoperative complications, such as postoperative surgical site infection, total hospital length of stay, 30-day mortality, and unplanned 30-day readmission. RESULTS: From January 2009 to June 2023, there were 42 lower extremity bypasses performed in patients who possessed inadequate GSV. All procedures were performed in men (n = 42, 100%). The median age was 67 years (interquartile range (IQR) 62-71 years). Nine procedures (21.4%) were performed for claudication, 21 (50%) for tissue loss, and 12 (28.6%) for rest pain. The majority involved bypassing to infrageniculate targets (n = 39, 93%). Conduit composition included single (n = 19, 45%), two-piece (n = 19, 45%), or three-piece (n = 4, 10%) composite grafts with arm vein. The median AFS was 3.86 years (IQR 1.19-6.65 years). Five patients required major amputation (15.6%). The median time to MALE was 0.88 years (IQR 0.23-1.69 years). Overall, 30-day mortality was 2.4% (n = 1). Postoperative complications included surgical site infection in 9 patients (21.4%), hematoma in 3 patients (7.1%), early graft thrombosis in one patient (2.4%), wound dehiscence in one patient (2.4%), and a lymph leak in one patient (2.4%). The median length of stay was 6 days (IQR 3.3-9.5 days). CONCLUSION: Arm vein is a viable alternative autogenous conduit for lower extremity arterial bypasses in patients without adequate GSV.
引用
- Loanzon RS, Shafique H, Cui CL, et al. Outcomes After Utilization of Autogenous Arm Vein Grafts for Lower Extremity Bypasses. Ann Vasc Surg. 2025. PMID: 40816494. doi:10.1016/j.avsg.2025.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。